Corcept Therapeutics IncorporatedCORTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
3Y CAGR-40.0%
5Y CAGR-35.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-40.0%/yr
vs -35.4%/yr prior
5Y CAGR
-35.4%/yr
Recent deceleration
Acceleration
-4.6pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 3.25% |
| 2024 | 33.92% |
| 2023 | 40.74% |
| 2022 | 15.04% |
| 2021 | -0.78% |
| 2020 | 28.92% |
| 2019 | 18.30% |
| 2018 | 86.37% |
| 2017 | 69.33% |
| 2016 | 54.64% |